Trial Profile
A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2018
Price :
$35
*
At a glance
- Drugs Demcizumab (Primary) ; Carboplatin; Pembrolizumab; Pemetrexed
- Indications Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 26 Oct 2017 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
- 08 May 2017 According to a company media release, OncoMed is discontinuing the dosing of all patients on the demcizumab trials and will conduct a complete program review in the near term with its partner Celgene.
- 08 May 2017 Status changed from active, no longer recruiting to discontinued, according to an OncoMed Pharmaceuticals media release.